Digital CBT for Insomnia in Healthcare Workers
(HCW-CBTi Trial)
Trial Summary
What is the purpose of this trial?
The COVID-19 pandemic has resulted in increased workload and concerns about personal and family safety for frontline healthcare workers (HCWs), which can lead to decreased well-being and worsening mental health. Sleep disruption is particularly prevalent among HCWs providing frontline COVID-19 care. It can have direct consequences on their cognitive and emotional functioning, as well as on patient safety. Cognitive Behavioral Therapy for insomnia (CBTi) is a first-line treatment for insomnia. It has been shown to improve sleep health and wellbeing in the general population. However, there are significant barriers to delivering CBTi to frontline HCWs, including limited availability of trained sleep therapists and high costs. To address this, a Canada-wide randomized controlled trial is developed to determine the effectiveness of a digital CBTi program on the sleep health, mental health, wellness, and overall quality of life of frontline HCWs caring for COVID-19 patients. This study may provide an easily accessible and scalable sleep health intervention that can be included as part of a national and global response to the COVID-19 pandemic.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are participating in other psychological treatments or drug trials, you would not be eligible for this study.
What data supports the effectiveness of the treatment Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)?
Is digital CBT for insomnia safe for humans?
How is digital CBT for insomnia different from other treatments?
Digital CBT for insomnia is unique because it is delivered through digital platforms like smartphone apps, making it more accessible and scalable compared to traditional in-person therapy. It focuses on changing thoughts and behaviors related to sleep, which can improve sleep quality and daytime functioning without the need for medication.12457
Research Team
Mandeep Singh, MD, FRCPC
Principal Investigator
Associate Professor, Department of Anesthesiology and Pain Medicine, Toronto Western Hospital, UHN
Eligibility Criteria
This trial is for frontline healthcare workers experiencing insomnia, with a score of 16 or lower on the Sleep Condition Indicator. They must be actively involved in patient care during the COVID-19 pandemic and have access to a mobile phone or computer with internet. Those with urgent CBT needs, recent CBT treatment, additional sleep disorders like apnea or restless legs syndrome, severe medical/psychiatric conditions, or participating in other treatments/drug trials are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants in the intervention arm receive digital CBTi via the Sleepio app over 6 to 12 weeks, while the control group accesses sleep diary and education material for 12 weeks.
Follow-up
Participants are monitored for changes in sleep health, mental health, and overall quality of life after the treatment phase.
Treatment Details
Interventions
- Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)
Digital Cognitive Behavioral Therapy for Insomnia (dCBTi) is already approved in Canada, United States, European Union for the following indications:
- Insomnia
- Insomnia
- Insomnia
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor